Literature DB >> 19808368

Prognostic value of biomarkers in heart failure: application of novel methods in the community.

Shannon M Dunlay1, Yariv Gerber, Susan A Weston, Jill M Killian, Margaret M Redfield, Véronique L Roger.   

Abstract

BACKGROUND: Mortality among patients with heart failure is high. Though individual biomarkers have been investigated to determine their value in mortality risk prediction, the role of a multimarker strategy requires further evaluation. METHODS AND
RESULTS: Olmsted County residents presenting with heart failure from July 2004 to September 2007 were recruited to undergo biomarker measurement. We investigated whether addition of C-reactive protein, B-type natriuretic peptide, and troponin T to a model including established risk indicators improved 1-year mortality risk prediction using the c statistic, integrated discrimination improvement, and net reclassification improvement. Among 593 participants, the mean age was 76.4 years, and 48% were men. After 1 year of follow-up, 122 (20.6%) participants had died. Patients with C-reactive protein (<11.8 mg/L), B-type natriuretic peptide (<350 pg/mL), and troponin T (< or = 0.01 ng/mL) less than the median had low 1-year mortality (3.3%), whereas those with 2 or 3 biomarkers greater than the median had markedly increased mortality (30.8% and 35.5%, respectively). The addition of 2 or more biomarkers to the model offered greater improvement in 1-year mortality risk prediction than use of a single biomarker. The combination of C-reactive protein and B-type natriuretic peptide resulted in an increase in the c statistic from 0.757 to 0.810 (P<0.001), an integrated discrimination improvement gain of 7.1% (P<0.001), and a net reclassification improvement of 22.1% (P<0.001). Use of all 3 biomarkers offered no incremental gain (integrated discrimination improvement gain 0.7% versus C-reactive protein+B-type natriuretic peptide, P=0.065).
CONCLUSIONS: Biomarkers improved 1-year mortality risk prediction beyond established indicators. The use of a 2-biomarker combination was superior to a single biomarker in risk prediction, though addition of a third biomarker conferred no added benefit.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808368      PMCID: PMC2774116          DOI: 10.1161/CIRCHEARTFAILURE.109.849299

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  38 in total

1.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

Review 2.  Biomarkers in heart failure.

Authors:  Eugene Braunwald
Journal:  N Engl J Med       Date:  2008-05-15       Impact factor: 91.245

3.  Predictors of prognosis in patients with stable mild to moderate heart failure.

Authors:  P Bettencourt; A Ferreira; P Dias; J Pimenta; F Friões; L Martins; M Cerqueira-Gomes
Journal:  J Card Fail       Date:  2000-12       Impact factor: 5.712

4.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.

Authors:  Alan S Maisel; Padma Krishnaswamy; Richard M Nowak; James McCord; Judd E Hollander; Philippe Duc; Torbjørn Omland; Alan B Storrow; William T Abraham; Alan H B Wu; Paul Clopton; Philippe G Steg; Arne Westheim; Catherine Wold Knudsen; Alberto Perez; Radmila Kazanegra; Howard C Herrmann; Peter A McCullough
Journal:  N Engl J Med       Date:  2002-07-18       Impact factor: 91.245

Review 5.  Epidemiology and risk stratification in acute heart failure.

Authors:  Gregg C Fonarow
Journal:  Am Heart J       Date:  2007-11-26       Impact factor: 4.749

6.  Cardiac troponin and outcome in acute heart failure.

Authors:  W Frank Peacock; Teresa De Marco; Gregg C Fonarow; Deborah Diercks; Janet Wynne; Fred S Apple; Alan H B Wu
Journal:  N Engl J Med       Date:  2008-05-15       Impact factor: 91.245

7.  Use of multiple biomarkers to improve the prediction of death from cardiovascular causes.

Authors:  Björn Zethelius; Lars Berglund; Johan Sundström; Erik Ingelsson; Samar Basu; Anders Larsson; Per Venge; Johan Arnlöv
Journal:  N Engl J Med       Date:  2008-05-15       Impact factor: 91.245

8.  Predictive value of high sensitivity CRP in patients with diastolic heart failure.

Authors:  Yoav Michowitz; Yaron Arbel; Dov Wexler; David Sheps; Ori Rogowski; Itzhak Shapira; Shlomo Berliner; Gad Keren; Jacob George; Arie Roth
Journal:  Int J Cardiol       Date:  2007-04-30       Impact factor: 4.164

9.  Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association.

Authors:  Mark A Hlatky; Philip Greenland; Donna K Arnett; Christie M Ballantyne; Michael H Criqui; Mitchell S V Elkind; Alan S Go; Frank E Harrell; Yuling Hong; Barbara V Howard; Virginia J Howard; Priscilla Y Hsue; Christopher M Kramer; Joseph P McConnell; Sharon-Lise T Normand; Christopher J O'Donnell; Sidney C Smith; Peter W F Wilson
Journal:  Circulation       Date:  2009-04-13       Impact factor: 29.690

10.  Coronary disease surveillance in Olmsted County objectives and methodology.

Authors:  Véronique L Roger; Jill Killian; Mary Henkel; Susan A Weston; Tauqir Y Goraya; Barbara P Yawn; Thomas E Kottke; Robert L Frye; Steven J Jacobsen
Journal:  J Clin Epidemiol       Date:  2002-06       Impact factor: 6.437

View more
  21 in total

Review 1.  Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis.

Authors:  Alberto Ortiz; Ziad A Massy; Danilo Fliser; Bengt Lindholm; Andrzej Wiecek; Alberto Martínez-Castelao; Adrian Covic; David Goldsmith; Gültekin Süleymanlar; Gérard M London; Carmine Zoccali
Journal:  Nat Rev Nephrol       Date:  2011-11-01       Impact factor: 28.314

Review 2.  An update on cardiac troponins as circulating biomarkers in heart failure.

Authors:  Serge Masson; Roberto Latini; Inder S Anand
Journal:  Curr Heart Fail Rep       Date:  2010-03

3.  Assessing the Incremental Role of Novel and Emerging Risk Factors.

Authors:  Nancy R Cook
Journal:  Curr Cardiovasc Risk Rep       Date:  2010-03-01

4.  Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure.

Authors:  Michael R Zile; Stacia M Desantis; Catalin F Baicu; Robert E Stroud; Sheila B Thompson; Catherine D McClure; Shannon M Mehurg; Francis G Spinale
Journal:  Circ Heart Fail       Date:  2011-02-24       Impact factor: 8.790

Review 5.  Use of metformin in diseases of aging.

Authors:  John M Miles; Andrew D Rule; Barry A Borlaug
Journal:  Curr Diab Rep       Date:  2014-06       Impact factor: 4.810

6.  Predictors of re-hospitalization in patients with chronic heart failure.

Authors:  Melody Zaya; Anita Phan; Ernst R Schwarz
Journal:  World J Cardiol       Date:  2012-02-26

Review 7.  BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review.

Authors:  Pasqualina L Santaguida; Andrew C Don-Wauchope; Mark Oremus; Robert McKelvie; Usman Ali; Stephen A Hill; Cynthia Balion; Ronald A Booth; Judy A Brown; Amy Bustamam; Nazmul Sohel; Parminder Raina
Journal:  Heart Fail Rev       Date:  2014-08       Impact factor: 4.214

8.  Role of Cardiac Troponin Levels in Acute Heart Failure.

Authors:  Nicholas Wettersten; Alan Maisel
Journal:  Card Fail Rev       Date:  2015-10

Review 9.  The dilemma, causes and approaches to avoid recurrent hospital readmissions for patients with chronic heart failure.

Authors:  Melody Zaya; Anita Phan; Ernst R Schwarz
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

Review 10.  Incremental value of natriuretic peptide measurement in acute decompensated heart failure (ADHF): a systematic review.

Authors:  Pasqualina L Santaguida; Andrew C Don-Wauchope; Usman Ali; Mark Oremus; Judy A Brown; Amy Bustamam; Stephen A Hill; Ronald A Booth; Nazmul Sohel; Robert McKelvie; Cynthia Balion; Parminder Raina
Journal:  Heart Fail Rev       Date:  2014-08       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.